Johnson & Johnson (NYSE:JNJ) Shares Purchased by Lifeworks Advisors LLC

Lifeworks Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 25.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 53,792 shares of the company's stock after buying an additional 10,895 shares during the quarter. Johnson & Johnson accounts for 1.4% of Lifeworks Advisors LLC's investment portfolio, making the stock its 10th largest position. Lifeworks Advisors LLC's holdings in Johnson & Johnson were worth $7,779,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Intellectus Partners LLC raised its stake in shares of Johnson & Johnson by 4.9% in the fourth quarter. Intellectus Partners LLC now owns 9,770 shares of the company's stock valued at $1,413,000 after acquiring an additional 455 shares in the last quarter. Blankinship & Foster LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $744,000. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $5,037,000. Banco Santander S.A. boosted its stake in shares of Johnson & Johnson by 31.0% in the 4th quarter. Banco Santander S.A. now owns 40,803 shares of the company's stock valued at $5,901,000 after buying an additional 9,664 shares during the period. Finally, Machina Capital S.A.S. grew its position in shares of Johnson & Johnson by 6.8% during the fourth quarter. Machina Capital S.A.S. now owns 18,046 shares of the company's stock worth $2,610,000 after buying an additional 1,154 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on JNJ shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price on the stock. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Finally, Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Remove Ads

Johnson & Johnson Price Performance

Shares of JNJ opened at $166.81 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a 50-day simple moving average of $152.95 and a 200-day simple moving average of $156.28. The company has a market capitalization of $401.61 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company's stock, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.